Source: Healio News
Cristina Gasparetto, MD, director of the multiple myeloma program at Duke University, discussed data on bispecific T-cell engagers currently being studied in relapsed and refractory multiple myeloma presented at the virtual ASCO Annual Meeting
In a video interview, Gasparetto said that the data on bispecific T-cell engagers (BiTEs) has shown promising overall responses as well as mild to moderate toxicities in most patients.
“It looks like the administration of these BiTEs is going to be favorable for the quality of life for patients,” she said. “They are given once a week